Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular …
Over the last 12 months, insiders at Catalyst Pharmaceuticals, Inc. have bought $0 and sold $29.48M worth of Catalyst Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Catalyst Pharmaceuticals, Inc. have bought $130,960 and sold $16.03M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $89,100 was made by MCENANY PATRICK J (President and CEO) on 2020‑09‑30.
2024-12-10 | Sale | Chief Op. & Scientific Officer | 50,000 0.0417% | $21.93 | $1.1M | -2.69% | ||
2024-11-27 | Sale | Chief Med. & Reg. Officer | 12,000 0.0102% | $22.72 | $272,654 | -2.19% | ||
2024-11-27 | Sale | director | 17,500 0.0144% | $22.00 | $385,000 | -2.19% | ||
2024-11-26 | Sale | Chief Compliance/Legal Officer | 13,256 0.011% | $21.63 | $286,704 | +0.14% | ||
2024-11-20 | Sale | Chairman of Board of Directors | 72,500 0.0612% | $21.29 | $1.54M | +2.79% | ||
2024-11-20 | Sale | Chief Med. & Reg. Officer | 38,000 0.032% | $21.20 | $805,562 | +2.79% | ||
2024-11-19 | Sale | Chairman of Board of Directors | 98,345 0.0823% | $21.19 | $2.08M | -0.07% | ||
2024-11-14 | Sale | Chairman of Board of Directors | 44,655 0.0376% | $21.75 | $971,336 | -5.30% | ||
2024-11-13 | Sale | Chairman of Board of Directors | 92,500 0.0776% | $22.98 | $2.13M | -4.78% | ||
2024-11-12 | Sale | Chairman of Board of Directors | 262,000 0.221% | $23.26 | $6.09M | -5.71% | ||
2024-11-11 | Sale | Chairman of Board of Directors | 230,000 0.1936% | $23.55 | $5.42M | -7.29% | ||
2024-08-21 | Sale | director | 15,000 0.0124% | $20.10 | $301,455 | +3.25% | ||
2024-08-20 | Sale | Chief Op. & Scientific Officer | 150,000 0.1243% | $20.35 | $3.05M | +2.08% | ||
2024-08-09 | Sale | Chief Med. & Reg. Officer | 100,000 0.0826% | $18.04 | $1.8M | +13.12% | ||
2024-08-09 | Sale | Chief Commercial Officer | 36,058 0.0304% | $18.42 | $664,310 | +13.12% | ||
2024-06-07 | Sale | Chief Commercial Officer | 7,541 0.0066% | $16.07 | $121,184 | +30.09% | ||
2024-06-05 | Sale | Chief Med. & Reg. Officer | 80,000 0.0671% | $16.16 | $1.29M | +24.48% | ||
2024-06-04 | Sale | President and CEO | 17,323 0.0146% | $15.97 | $276,735 | +26.37% | ||
2024-06-03 | Sale | director | 5,333 0.0045% | $16.30 | $86,949 | +25.15% | ||
2024-04-08 | Sale | director | 25,000 0.0214% | $15.68 | $392,000 | +25.58% |
MCENANY PATRICK J | Chairman of Board of Directors | 4478169 3.7546% | $21.60 | 36 | 14 | +56.01% |
Miller Steve | Chief Op. & Scientific Officer | 686996 0.576% | $21.60 | 3 | 9 | +36.11% |
Tierney David S | director | 348874 0.2925% | $21.60 | 3 | 7 | +8.21% |
BIOMARIN PHARMACEUTICAL INC | 10 percent owner | 6666667 5.5894% | $21.60 | 1 | 0 | |
HUCKEL HUBERT E MD | director | 1304134 1.0934% | $21.60 | 5 | 0 |
BlackRock | $282.66M | 15.01 | 17.73M | +12.07% | +$30.45M | 0.01 | |
Deerfield Management | $145.55M | 7.73 | 9.13M | +2.72% | +$3.86M | 0.36 | |
State Street | $129.96M | 6.9 | 8.15M | +20.12% | +$21.77M | 0.01 | |
The Vanguard Group | $127.21M | 6.76 | 7.98M | +12.08% | +$13.71M | <0.01 | |
Dimensional Fund Advisors | $43.64M | 2.32 | 2.74M | +5.22% | +$2.17M | 0.01 |